AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Date of Call: November 11, 2025
$90 million for Q1 2026, more than 4x the level of just a few short quarters ago. - The company's revenue increased by 79% to $15.1 million in Q1 2026 compared to $8.4 million in the same year-ago quarter. - 
66% of LightPath's backlog is now in systems and subsystems, reflecting a strategic shift from components.The transition is part of the company's strategy to move up the value chain and capture more of the value created in the photonics industry.
Strategic Investments and Partnerships:
$8 million strategic investment from Ondas Holdings and Unusual Machines to support its commercialization roadmap.The partnership is intended to accelerate commercialization, particularly around uncooled infrared solutions for drone applications.
Germanium-Free Technology and Supply Chain Resiliency:

Overall Tone: Positive
Contradiction Point 1
Capacity Expansion and Production Ramp
It involves the company's strategic approach to meeting increased demand through capacity expansion, impacting production timelines and revenue projections.
How quickly are you transitioning your camera and subassembly portfolio to BlackDiamond glass? - Richard Shannon(Craig-Hallum Capital Group)
2026Q1: LightPath is focused on converting our portfolio of cameras and subassemblies to BlackDiamond glass, which is critical to long-term growth. This conversion process is ongoing. - Sam Rubin(CEO)
What does the Visimid capacity expansion signal, and what other work will it handle besides the Lockheed contract? - Glenn Mattson(Ladenburg Thalmann & Co.)
2025Q4: We are seeing extremely strong demand for our NGSRI and border security cameras, and we have expanded our capacity at Visimid to meet this increased demand. - Sam Rubin(CEO)
Contradiction Point 2
Growth Opportunities and Revenue Projections
It involves the company's outlook on growth opportunities and revenue projections, which are crucial for investor expectations.
How many $10M+ annual revenue opportunities are in the pipeline? - Jaeson Schmidt(Lake Street Capital Markets)
2026Q1: We currently have about 7 such opportunities, with counter-UAS and larger system programs contributing. - Sam Rubin(CEO)
What was G5's contribution to Q2 revenue? Additionally, how much of the $90 million backlog is from G5? - Jaeson Schmidt(Lake Street Capital Markets)
2025Q4: We have about $90 million of backlog on our books already reflecting our strong pipeline of orders, which we expect to ship over the next fiscal years 2026 and 2027. - Albert Miranda(CFO)
Contradiction Point 3
Germanium and BlackDiamond Glass Supply and Demand
It involves the company's strategic positioning and resource allocation in response to evolving material supply constraints, which could affect production capabilities and financial performance.
How are you addressing germanium and BlackDiamond glass with China opening a window for overseas germanium acquisitions? - Richard Shannon (Craig-Hallum Capital Group LLC)
2026Q1: The germanium situation changes daily, but China remains cautious about using germanium in defense applications. Customers are switching to BlackDiamond due to supply chain concerns. The transition pace is limited by resources, but priorities are currently on short-term revenue. - Sam Rubin(CEO)
What caused the delays in the Apache program? - Glenn Mattson (Ladenburg Thalmann)
2025Q3: We continue to work closely with our suppliers. As I mentioned earlier in my prepared remarks, we've had our own glass production ready to go for a while, and we've just been waiting for the glass to start the production ramp. And now we are on a known path towards resolution. - Sam Rubin(CEO)
Contradiction Point 4
Capacity Expansion and Gross Margin Expectations
It involves changes in operational strategies and financial forecasts, specifically regarding capacity expansion and gross margin expectations, which are critical for investor confidence and business planning.
What steps are you taking to improve capacity internally or through external suppliers, and how long will resolution take? - Richard Shannon (Craig-Hallum Capital Group LLC)
2026Q1: Capacity additions are needed across all production areas due to strong demand. Vendors may face constraints, but most components are vertically integrated. Investments in glass and new facilities are planned to accommodate growth. - Sam Rubin(CEO)
Are there capacity constraints on the G5 side, and can production be moved to Orlando? - Scott Buck (H. C. Wainwright)
2025Q3: Capacity constraints on the G5 side are minimal with the ability to add shifts and trained workforce. Detector supply is secured with large orders, and LightPath can provide optical components if needed. Overall, capacity is not a concern. - Sam Rubin(CEO)
Contradiction Point 5
Impact of Supply Chain Constraints
It highlights differing perspectives on how supply chain constraints have affected the company's operations, which could influence investor perceptions regarding the company's resilience and adaptability.
How are you addressing germanium and BlackDiamond glass given China’s recent opening of a window for overseas germanium acquisitions? Additionally, how quickly are you transitioning your camera and subassembly portfolio to BlackDiamond glass? - Richard Shannon(Craig-Hallum Capital Group LLC)
2026Q1: The yield issues in the quarter were not particularly bad, only normal in nature. However, due to the lack of extra materials from China, the yield issues became amplified, causing delays in delivery. - Sam Rubin(CEO)
How are Chinese supply chain disruptions affecting this quarter? - Orin Hirschman(AIGH Investment Partners)
2025Q2: We've shipped most of the impacted orders already in the first six weeks of this quarter. The supply chain from China is still slow, causing uncertainty about order fulfillment for the rest of the quarter. - Albert Miranda(CFO)
Discover what executives don't want to reveal in conference calls

Dec.04 2025

Dec.04 2025

Dec.04 2025

Dec.04 2025

Dec.04 2025
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet